Type and location of fluorescent probes incorporated into the potent mu-opioid peptide [Dmt]DALDA affect potency, receptor selectivity and intrinsic efficacy.
The dermorphin-derived tetrapeptide H-Dmt-d-Arg-Phe-Lys-NH(2) (Dmt = 2',6'-dimethyltyrosine) ([Dmt(1)]DALDA) is a highly potent and selective mu-opioid agonist capable of crossing the blood-brain barrier and producing a potent, centrally mediated analgesic effect when given systemically. For the purpose of biodistribution studies by fluorescence techniques, [Dmt(1)]DALDA analogues containing various fluorescent labels [dansyl, anthraniloyl (atn), fluorescein, or 6-dimethylamino-2'-naphthoyl] in several different locations of the peptide were synthesized and characterized in vitro in the guinea-pig ileum and mouse vas deferens assays, and in mu-, delta- and kappa-opioid receptor-binding assays. The analogues showed various degrees of mu receptor-binding selectivity, but all of them were less mu-selective than the [Dmt(1)]DALDA parent peptide. Most analogues retained potent, full mu-agonist activity, except for one with fluorescein attached at the C-terminus (3a) (partial mu-agonist) and one containing beta-(6'-dimethylamino-2'-naphthoyl)alanine (aladan) in place of Phe(3) (4) (mu- and kappa-antagonist). The obtained data indicate that the receptor-binding affinity, receptor selectivity and intrinsic efficacy of the prepared analogues vary very significantly, depending on the type of fluorescent label used and on its location in the peptide. The results suggest that the biological activity profile of fluorescence-labeled peptide analogues should always be carefully determined prior to their use in biodistribution studies or other studies. One of the analogues containing the atn group (2a) proved highly useful in a study of cellular uptake and intracellular distribution by confocal laser scanning microscopy.
Schiller
P W
PW
Laboratory of Chemical Biology and Peptide Research, Clinical Research Institute of Montreal, 110 Pine Avenue West, Montreal, Quebec, Canada H2W 1R7. schillp@ircm.qc.ca
Berezowska
I
I
Weltrowska
G
G
Chen
H
H
Lemieux
C
C
Chung
N N
NN
D015081:2-Naphthylamine / Q000031:analogs & derivatives; D000409:Alanine / Q000031:analogs & derivatives; D000818:Animals; D003619:Dansyl Compounds; D005452:Fluoresceins; D005456:Fluorescent Dyes; D051379:Mice; D009842:Oligopeptides / Q000737:chemistry* / Q000378:metabolism; D017450:Receptors, Opioid, mu / Q000737:chemistry* / Q000378:metabolism*; D014443:Tyrosine / Q000031:analogs & derivatives* / Q000737:chemistry / Q000378:metabolism; D062367:ortho-Aminobenzoates
D003619:Dansyl Compounds; D005452:Fluoresceins; D005456:Fluorescent Dyes; D009842:Oligopeptides; D017450:Receptors, Opioid, mu; C459091:aladan; D062367:ortho-Aminobenzoates; C063076:tyrosyl-arginyl-phenylalanyl-lysinamide; C076121:2',6'-dimethyltyrosine; C078242:5-(aminomethyl)fluorescein; D014443:Tyrosine; D015081:2-Naphthylamine; D000409:Alanine